Sabroe R A, Greaves M W
Department of Dermatology, Barnsley Hospital NHS Foundation Trust, Gawber Road, Barnsley S75 2EP, UK.
Br J Dermatol. 2006 May;154(5):813-9. doi: 10.1111/j.1365-2133.2006.07183.x.
It is now recognized that approximately one-third of patients with chronic idiopathic urticaria (CIU) have histamine-releasing autoantibodies directed against either the high-affinity IgE receptor or, less frequently, against IgE. However, there are several unsolved problems relating to the role of such autoantibodies in the disease. Additionally, it is not clear whether CIU with autoantibodies can be classified as an autoimmune disease. The detection of patients with autoantibodies also poses challenges. Firstly, the only in vivo method, the autologous serum skin test, is at best 80% sensitive and specific using in vitro basophil histamine release assays as the verum. Secondly, in vitro tests are only done in a small number of research laboratories, and are not widely commercially available, and thirdly, there is some divergence between results obtained by different methods (functional and immunoassays) used to detect patients with autoantibodies. The presence of autoantibodies may be important clinically in a small group of severely affected, treatment-resistant patients, where immunomodulatory treatments may be helpful.
目前已认识到,大约三分之一的慢性特发性荨麻疹(CIU)患者具有针对高亲和力IgE受体或较少针对IgE的组胺释放自身抗体。然而,关于此类自身抗体在该疾病中的作用仍存在几个未解决的问题。此外,具有自身抗体的CIU是否可归类为自身免疫性疾病尚不清楚。自身抗体患者的检测也面临挑战。首先,唯一的体内方法,即自体血清皮肤试验,以体外嗜碱性粒细胞组胺释放试验作为参照标准时,其敏感性和特异性最高仅为80%。其次,体外试验仅在少数研究实验室进行,尚未广泛商业化,第三,用于检测自身抗体患者的不同方法(功能测定和免疫测定)所获得的结果存在一些差异。在一小部分病情严重、治疗抵抗的患者中,自身抗体的存在可能在临床上具有重要意义,免疫调节治疗可能会有所帮助。